A Report on Using Implanted Devices to Manage Chronic Pain

Nina Stubhaug*
Department of Anesthesiology, Lovisenberg Diakonale Hospital, Oslo, Norway

Description

Patients frequently seek treatment from a variety of healthcare professionals for their chronic pain problem. This kind of pain frequently receives improper or insufficient care and causes great misery and incapacity. Before beginning treatment, patients seeking evaluation for chronic pain should go through a thorough evaluation. Patients with chronic pain frequently complain of sadness, difficulty sleeping, exhaustion, and a general decline in physical and mental capacity. They frequently call for an interdisciplinary approach to care to enable medical professionals to deal with the various aspects of the patient’s pain experience. Following a thorough assessment, therapy options may include prescription drugs, nerve blocks, active physical therapy, behavioural therapies, and support for vocational assessment and training. Implanted devices may be inserted as part of therapy less frequently to change how pain is felt.

These patients have a chronic illness and frequently need long-term care with ongoing therapy evaluations and adjustments. Although there is a chance of recovery, it is rare. The purpose of therapy is to lessen pain and suffering while enhancing both physical and mental functioning. The therapy of chronic pain has become increasingly popular in recent years. The aim of this study was to identify and analyse problems and patterns in legal responsibility connected to anesthesiologists' management of chronic pain. Stable chronic pain can be effectively managed by implanted pumps that administer intrathecal medications. The proper management of unpredictable pain swings is still difficult, though [1].

The use of patient-controlled analgesia (PCA) using a special tool—the personal treatment manager (PTM)—designed to be used with implanted programmable pumps is one potential remedy. The use of a PTM with a programmable, implantable pump system for patient-controlled analgesia is a successful therapy for the management of chronic pain and gives patients a sense of increased control over unpredictable pain swings. The US FDA has given the Bioess, Inc. (CA, USA) StimRouter® peripheral nerve stimulation system approval for the treatment of peripheral mononeuropathy resistant to conventional medical care [2]. The StimRouter is a minimally invasive system that produces peripheral neuromodulation and relieves pain by using an external pulse generator and a subcutaneously implanted line with integrated anchor and electrodes.

The StimRouter system has a large margin of safety, setting it apart from other peripheral neuromodulation systems that call for open surgical electrode implantation and implantable pulse generators, according to a number of published clinical trials reviewed here. These trials have also demonstrated the StimRouter system's effectiveness in treating a variety of peripheral mononeuropathies, enhancing patients' quality of life, activity levels, and pain levels. A workable approach for treating persistent peripheral mononeuropathy is StimRouter [3]. Over 100 million Americans experience chronic pain each year, with low back and hip discomfort being particularly prevalent. Over the past ten years, the usage of radiofrequency ablation (RFA), which has specific advantages over other chronic pain management techniques, has grown.

RFA and its potential to interfere with implantable cardiac devices are of concern among the expanding population who suffer from concomitant conduction abnormalities and chronic discomfort. RFA has been demonstrated to be beneficial in a variety of chronic pain disorders and is quickly becoming a cornerstone of persistent pain therapy. For many years, cardiac conduction problems have been treated with cardiac implantable electronic devices (CIED), such as implantable cardioverter defibrillators and cardiac pacemakers [4]. Both the incidence and prevalence of these diseases have increased with the ageing of our population. Our ageing population is prone to both cardiac conduction disorders and chronic discomfort. Over 100 million Americans, many of whom are older, experience chronic pain every year.

Estimates of yearly total health care costs range from $560 to $635 billion, primarily as a result of lost productivity and decreased pay. Over 80% of people worldwide experience low back pain, one of the most prevalent types of chronic pain, which accounts for over $100 billion in annual costs. Radiofrequency ablation (RFA) treatment is one of the significant advancements in pain management during the past few decades. RFA has been successfully utilised for more than 40 years to treat a variety of cardiac arrhythmias, including various forms of chronic discomfort. RFA has recently established itself as a go-to method for treating chronic pain.

An insulated needle is used to transmit a high-frequency electrical current that generates thermal energy and causes a lesion inside the nerve, impairing the nerve's ability to send pain signals. RFA is beneficial in treating lumbar facet joint and sacroiliac joint pain, 2 of the most frequent sites for persistent pain, according to a comprehensive analysis published in 2014. RFA has also shown promise in treating osteoarthritic knee pain. Radiographic evidence of osteoarthritic alterations in the knee is present in 37% of Americans, while knee pain due to arthritis is present in 14% of people [5].

RFA has also been used successfully for radicular pain, sacroiliac joint pain, postsurgical pain, shoulder pain, and myofascial pain, among other chronic pain syndromes. In addition, RFA provides a lot of benefits over traditional pain relief methods. It is a great choice for nonsurgical candidates, patients who have tried other treatments without success, or people for whom corticosteroid injections are not recommended. The non-invasive nature and flexibility to repeat as necessary are further advantages.

Conflict of Interest

Author declares no conflicts.

References


